Spectrum Exits the Poziotinib Exon 20 Program: Four Trials Halted, Stated Reasons Explicitly Exclude Safety

What Happened

Spectrum Pharmaceuticals has terminated its flagship Phase 2 poziotinib study in NSCLC — NCT03318939, a multi-center, open-label, seven-cohort trial that enrolled 648 participants targeting EGFR or HER2 Exon 20 insertion mutations, with Objective Response Rate (ORR) as the primary endpoint ^[1]. The study ran from 2017-10-11 through a primary completion date of 2023-04-03 ^[1]. The stated termination reason: "strategic business decision (unrelated to safety)" ^[1].

This termination does not stand alone. Spectrum's Phase 3 confirmatory study — NCT05378763, a randomized comparison of poziotinib versus docetaxel in previously treated, locally advanced or metastatic NSCLC with HER2 Exon 20 mutations, designed to enroll 268 participants with Progression-Free Survival (PFS) as the primary endpoint, originally targeting primary completion by 2027-12-25 — is currently suspended with zero patients enrolled ^[2]. The ClinicalTrials.gov why-stopped statement is unambiguous: "The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA." ^[2]

Two additional trials complete the picture. Spectrum's Phase 1/2 study in Japanese NSCLC patients (NCT04402008, N=42, initiated 2020-06-23) was terminated for a "business decision, not related to safety" ^[4]. A parallel Phase 2 study run independently by MD Anderson Cancer Center (NCT03066206, planned N=93, started 2017-03-17, primary completion 2026-02-16) was terminated due to "<75% participation" ^[3].

Across every Spectrum-sponsored termination, safety is explicitly excluded as a causative factor by the stated why-stopped language ^[1][4]. The carve-out is consistent across geographies and study phases.

Why It Matters

The pattern across four trials matters more than any individual termination. Spectrum's Phase 2 (NCT03318939, N=648, primary completion 2023-04-03) was terminated citing a non-safety business decision ^[1], while its Phase 3 (NCT05378763, initiated 2022, planned N=268) ran in parallel before being suspended with zero patients enrolled ^[2]. The sponsor's own why-stopped language states that the study design is under active FDA revision ^[2] — suggesting the confirmatory design required rework before enrollment could proceed.

Poziotinib is a pan-HER/EGFR inhibitor, targeting the ErbB receptor family (ChEMBL ID: CHEMBL3545154; molecular target CHEMBL2363049) ^[5]. The compound reached Phase 3 — the highest development phase on record — before this sequence of halts ^[5]. A pan-HER approach by definition sweeps broader than a mutation-selective agent, and in Prognyx's reading, that distinction may be one factor shaping how regulators calibrate the confirmatory-trial bar in biomarker-defined oncology populations. The Phase 3 why-stopped language places FDA and Spectrum in active design negotiation ^[2]; the FDA's specific objections are not disclosed in public sources as of this briefing.

Prognyx could not confirm from public sources the ORR outcomes from NCT03318939 cohorts, the precise FDA feedback driving the Phase 3 redesign, or whether Spectrum has taken any commercial or balance-sheet action on poziotinib. The strategic rationale behind the "business decision" framing in the Phase 2 and Japanese study terminations ^[1][4] is not in the public record.

Who Is Exposed / Who Gained

Spectrum: The most direct exposure. Three Spectrum-sponsored studies (NCT03318939, NCT05378763, NCT04402008) — spanning Phase 1/2 through Phase 3, across US and Japanese cohorts — are terminated or suspended. NCT05378763 carries the most consequential status: suspended, not terminated, meaning Spectrum nominally retains the option of a redesigned study ^[2], but enrolled zero patients over the life of the trial. No public disclosure identifies a successor poziotinib program or a replacement NSCLC asset.

The EGFR/HER2 Exon 20 insertion NSCLC field: Spectrum's exit creates competitive room in a clinically validated subpopulation. The indication attracted multiple parallel programs — including NCT03318939, NCT03066206, and NCT05378763 — and the withdrawal of Spectrum's resources leaves the indication to programs that can satisfy whatever regulatory design standard is now emerging from the NCT05378763 FDA dialogue. Prognyx cannot confirm the approval status or efficacy data for competing agents in this specific Exon 20 subpopulation from the sources in this dossier; that competitive picture requires a dedicated update.

MD Anderson (NCT03066206): The independent academic track closed on low-participation grounds, not a sponsor decision ^[3]. Any efficacy signal from that cohort would require a separate publication search; none is confirmed here.

What to Watch Next

• NCT05378763 ClinicalTrials.gov status: The Phase 3 is suspended pending FDA-negotiated redesign ^[2]. No resolution timeline is publicly disclosed. Any record update — a shift from Suspended to Terminated, a revised protocol upload, or a new primary completion date — is the first public signal of how this dialogue closes. Watch NCT05378763 directly.
• NCT03066206 data disclosure: MD Anderson's study (primary completion 2026-02-16) closed before full enrollment ^[3]. If partial efficacy data appear in a peer-reviewed publication or at a major oncology congress, they represent the only remaining independent clinical read on poziotinib in this population.
• Spectrum pipeline communications: No SEC filing, press release, or IND amendment disclosing a poziotinib out-license, write-down, or successor program is present in public sources as of this briefing. Any such disclosure would materially define whether this is a program exit or an asset transfer.

The Now-What

1. Monitor NCT05378763 for resolution. The Phase 3 is suspended — not terminated — leaving Spectrum the technical option of a redesigned study ^[2]. If FDA and Spectrum converge on a modified design (revised population, endpoint, or comparator arm), poziotinib could re-enter the race. The window is open; no timeline is public. Any ClinicalTrials.gov status change is the trigger.

2. Treat the Exon 20 space as consolidating and update competitive intelligence accordingly. The three Spectrum-sponsored study halts — two terminations and one suspension — across US and Japanese cohorts are a strong structural signal. Any program building a Phase 3 package in EGFR or HER2 Exon 20 NSCLC should treat the FDA's on-record concern about the NCT05378763 design — whatever that concern is — as a precedent that now lives in the public domain. A competitive landscape update incorporating active agents in this subpopulation is warranted; this briefing does not have the data to execute it.

3. Track poziotinib's asset status for deal-flow signals. If Spectrum out-licenses or formally terminates internal development, poziotinib's Phase 3-grade clinical history — even a suspended one — retains residual value for a partner willing to address the study design problem. No such transaction is announced as of this briefing. A Phase 3 record and a seven-cohort Phase 2 dataset do not disappear on termination.

Verdict: Moderate-to-high strategic signal for any company advancing a pan-HER inhibitor toward Phase 3 in EGFR/HER2 Exon 20 NSCLC — the Spectrum/FDA impasse on NCT05378763 design is a live, on-record precedent. The window to incorporate it into protocol assumptions and competitive positioning is now.